InMed Sets November 4 Vote on Mentari Reverse Merger; Existing Holders to Own Just 0.97%
INM has more than doubled off its 52-week low of $0.575 on light trading volume (0.1× avg).
Summary
InMed's amended S-4 sets a November 4, 2026 shareholder vote on its reverse merger with Mentari Therapeutics. Existing InMed holders will own just 0.97% of the combined company, with Mentari securityholders holding 99.03%. The deal is critical for InMed, which faces a going concern qualification and Nasdaq delisting.
Updates
· SEC 424B3 — The 424B3 proxy statement sets the shareholder meeting for November 4, 2026, and details the reverse stock split range of 1-for-2 to 1-for-20.
Key Events · M&A and Partnerships · INM
-
Shareholder Vote Set for November 4
InMed shareholders will vote on the Mentari reverse merger at a virtual meeting on November 4, 2026. Record date is September 25, 2026, with 5,493,735 InMed Common Shares outstanding.
-
Existing Holders Diluted to 0.97%
Post-merger, InMed securityholders will own approximately 0.97% of the combined company on a fully-diluted basis, with Mentari securityholders holding 99.03%. The Exchange Ratio is estimated at 2.0065 InMed shares per Mentari share.
-
$490M Pre-Closing Financing
Mentari's pre-closing financing has an aggregate commitment of approximately $490.0 million, including $50.0 million from convertible notes. Investors include Fairmount, Commodore Capital, Deep Track Capital, Janus Henderson, a16z Bio + Health, and others.
-
Reverse Stock Split to Meet Nasdaq Listing
InMed plans a reverse stock split in the range of 1-for-2 to 1-for-20 to meet Nasdaq's $4.00 minimum bid price initial listing requirement. The combined company is expected to have approximately 528.0 million shares outstanding post-merger.
Analysis · INM · Life Sciences
InMed's Amendment No. 2 to its S-4 registration statement finalizes the shareholder vote date for the all-stock reverse merger with Mentari Therapeutics. The filing confirms existing InMed shareholders will own approximately 0.97% of the combined company on a fully-diluted basis, with Mentari securityholders holding 99.03%. The deal is existential for InMed: the company has a going concern qualification, $2.2M cash runway into September 2026, and a Nasdaq delisting notice for failing the $2.5M minimum shareholders' equity requirement. The merger is the primary path forward; failure to close would likely force liquidation. The filing also details a $490M pre-closing financing for Mentari, a 1-for-2 to 1-for-20 reverse stock split to meet Nasdaq's $4.00 bid price requirement, and a November 4, 2026 shareholder meeting.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INM was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6M. The 52-week trading range was $0.58 to $2.50. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.